Boenning & Scattergood Inc. boosted its stake in shares of Amgen, Inc. (NASDAQ:AMGN) by 4.1% in the first quarter, HoldingsChannel.com reports. The firm owned 5,078 shares of the medical research company’s stock after purchasing an additional 200 shares during the quarter. Boenning & Scattergood Inc.’s holdings in Amgen were worth $965,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other hedge funds also recently added to or reduced their stakes in AMGN. Ruggie Capital Group boosted its position in Amgen by 297.1% during the fourth quarter. Ruggie Capital Group now owns 135 shares of the medical research company’s stock worth $26,000 after purchasing an additional 101 shares during the period. Capital Financial Planning LLC bought a new position in Amgen during the fourth quarter worth $27,000. Massey Quick Simon & CO. LLC boosted its position in Amgen by 710.5% during the fourth quarter. Massey Quick Simon & CO. LLC now owns 154 shares of the medical research company’s stock worth $30,000 after purchasing an additional 135 shares during the period. Next Capital Management LLC bought a new stake in shares of Amgen in the fourth quarter valued at about $33,000. Finally, Essex Investment Management Co. LLC bought a new stake in shares of Amgen in the fourth quarter valued at about $39,000. 78.01% of the stock is owned by hedge funds and other institutional investors.
A number of equities research analysts have recently issued reports on the stock. Zacks Investment Research cut shares of Amgen from a “buy” rating to a “hold” rating in a research report on Friday, April 5th. Mizuho reissued a “buy” rating and issued a $208.00 target price on shares of Amgen in a research report on Friday, May 17th. JPMorgan Chase & Co. reissued a “hold” rating and issued a $190.00 target price on shares of Amgen in a research report on Wednesday, May 15th. Credit Suisse Group assumed coverage on shares of Amgen in a research report on Monday, May 20th. They issued an “outperform” rating and a $208.00 target price for the company. Finally, Royal Bank of Canada reissued a “neutral” rating and issued a $192.00 target price on shares of Amgen in a research report on Tuesday. One equities research analyst has rated the stock with a sell rating, nine have issued a hold rating and eleven have issued a buy rating to the company. The company has an average rating of “Hold” and an average target price of $209.05.
In related news, Director Ronald D. Sugar sold 2,000 shares of the business’s stock in a transaction dated Wednesday, May 1st. The stock was sold at an average price of $175.73, for a total value of $351,460.00. Following the completion of the transaction, the director now owns 15,092 shares of the company’s stock, valued at $2,652,117.16. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In the last ninety days, insiders sold 6,000 shares of company stock valued at $1,115,580. 0.25% of the stock is owned by insiders.
AMGN stock opened at $171.28 on Friday. The stock has a market capitalization of $104.47 billion, a P/E ratio of 11.89, a P/E/G ratio of 2.24 and a beta of 1.15. Amgen, Inc. has a 52 week low of $166.30 and a 52 week high of $210.19. The company has a debt-to-equity ratio of 2.71, a current ratio of 2.77 and a quick ratio of 2.53.
Amgen (NASDAQ:AMGN) last posted its quarterly earnings results on Tuesday, April 30th. The medical research company reported $3.56 EPS for the quarter, beating the Zacks’ consensus estimate of $3.45 by $0.11. The business had revenue of $5.56 billion during the quarter, compared to the consensus estimate of $5.55 billion. Amgen had a return on equity of 71.02% and a net margin of 34.00%. Amgen’s revenue for the quarter was up .1% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $3.47 earnings per share. On average, sell-side analysts predict that Amgen, Inc. will post 13.94 earnings per share for the current fiscal year.
The business also recently declared a quarterly dividend, which will be paid on Friday, June 7th. Investors of record on Friday, May 17th will be paid a $1.45 dividend. This represents a $5.80 dividend on an annualized basis and a yield of 3.39%. The ex-dividend date is Thursday, May 16th. Amgen’s dividend payout ratio (DPR) is presently 40.28%.
ILLEGAL ACTIVITY WARNING: “Amgen, Inc. (AMGN) Shares Bought by Boenning & Scattergood Inc.” was first published by Zolmax and is owned by of Zolmax. If you are accessing this news story on another site, it was illegally copied and reposted in violation of international trademark & copyright legislation. The correct version of this news story can be viewed at https://zolmax.com/investing/amgen-inc-amgn-shares-bought-by-boenning-scattergood-inc/3094685.html.
Amgen Company Profile
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells.
See Also: What is the Quick Ratio?
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.